Skip to main content
. 2021 Dec 22;14(1):16. doi: 10.3390/v14010016

Figure 2.

Figure 2

Total RAS prevalence among European failures, per different treatment region. Samples which include a RAS are divided by the total number of available sequences of that specific geno-/subtype and target region. The occurrence of RAS in rare subtypes is outlined in Table 2. No individuals with GT2c, GT3a, GT4a/d patients failed on NS5B non-nucleoside analogues with an available NS5B sequence.